---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-008706"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:21:28.692133+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro enters $25M financing via preferred stock and warrants at 15% dividend

## Summary
- Initial $500,000 closing of 50 Series A Preferred shares at $10,000 each; up to $25M total.
- Preferred shares convertible at floor $0.25 or 80% of 3-day lowest close (capped at $1.50).
- Warrants for up to 20M common shares at $1.25, exercisable for 5 years, subject to adjustment.
- 15% annual cumulative dividend payable in cash or additional preferred shares at investor's election.
- Proceeds to fund additional clinical trials for Alzheimer's, bipolar, MDD, PTSD; closing expected May 10, 2024.

## SEC filing metadata
- accession: 0001214659-24-008706
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/0001214659-24-008706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/p582408k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-008706
- JSON: https://secwatch.observer/filing/0001214659-24-008706.json
- Plain text: https://secwatch.observer/filing/0001214659-24-008706.txt

## Key facts
- Material Agreements
  Alzamend Neuro, Inc. entered into Securities Purchase Agreement with a sophisticated investor valued at up to $25,000,000.00 (effective 2024-05-08).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a sophisticated investor
  - Value: up to $25,000,000.00
  - Effective: 2024-05-08
  source text: On May 8, 2024 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to sell to the Purchaser up to 2,500 shares of Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) and warrants (the “ Warrants ”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) for a total purchase price of up to $25,000,000.00 (the “ Financing ”) in several tranche closings
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/0001214659-24-008706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.